Ono Pharmaceutical Co., Ltd. (4528.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Ono Pharmaceutical Co., Ltd.
Address
8-2, Kyutaromachi 1-chome
Osaka, OS 541-8564
Japan
Phone
81 6 6263 5670
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
4206
First IPO Date
January 04, 2001
Key Executives
| Name | Title | Pay | Year Born |
| Gyo Sagara | Chief Executive Officer & Chairman of the Board | 142M | 1958 |
| Toshihiro Tsujinaka | Corp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir | 78M | 1964 |
| Toichi Takino | President, Chief Operating Officer & Representative Director | 102M | 1968 |
| Tatsuya Okamoto | Corporate Officer & Executive Director of Clinical Development, Oncology Clinical Development Div. | 0 | N/A |
| Shinji Takai | Corporate Officer & Head of Medical Affairs | 0 | N/A |
| Thomas Lechner | Vice President of Medical Affairs | 0 | N/A |
| Akira Takada | Corporate Executive Officer & Executive Director of CMC & Production | 0 | N/A |
| Hiroyuki Takahashi | Director of Oncology Business Division | 0 | N/A |
| Satoshi Takahagi | Senior Director of EHS Promotion & Corporate Officer | 0 | N/A |
| Hiromu Habashita | Corporate Officer, Senior Vice President, Discovery & Research | 0 | N/A |
| Takehiro Yamada | Corporate Officer & Head of Risk and Compliance Management Department | 0 | N/A |
| Masayuki Tanigawa | Corporate Officer, Executive VP of Business Strategy & VP of License | 0 | N/A |
| Masaki Ito | Corporate Executive Officer and Div. Director of Corporate Strategy, Planning & Bus. Management Div. | 0 | N/A |
Description
Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
